A Saint Louis University researcher has received a grant to study the pathways from chronic prescription; opioid use to new onset mood disorder. “They hope our findings will inform pain management and safe opioid prescribing for patients with chronic, non-cancer pain,” Scherrer said. The grant will build upon Scherrer’s previous findings that indicate a new period of opioid analgesic use lasting beyond 30 days is associated with increased risk of new-onset depression.
Therefore in several previous studies controlling for pain; researchers found long-term (more than 90 days); opioid analgesic use is associated with increased risk for depression and impairs depression treatment and recovery. So this project collects data from 1,500 patients using prescription; opioids to identify factors that may increase the risk of opioid-related depression. But data collection will occur at three sites across the United States.
Psychiatric and substance abuse
The study will collect baseline, six month and 12-month measures of pain, functioning; psychiatric and substance abuse disorders, sleep, social support and quality of life. Participants will also asked to complete a brief monthly survey to measure rapid changes in pain, opioid use, and depression.
“They found that patients with depression 22 % more likely to develop treatment-resistant depression; with opioid use of 31-90 days and 49 % more likely if they used opioids for more than 90 days,” Scherrer said. “The consistency of our findings; replication in VA and in private sector patients and rigorous control for pain; support the theory that opioid analgesic use is likely a risk factor for depression.”
The sequence of pain
“The electronic medical records do not contain prospective data on the sequence of pain, opioid analgesic use, and depression symptom development,” Scherrer said. “Our key objectives are first to determine if patients with a prior history of depression are most likely to develop a new episode following prescription opioid use.”
Scherrer also wants to determine if opioid-related adverse outcomes, such as opioid misuse and sleep apnea that occur after long-term opioid use subsequently contribute to new-onset depression. Next, they want to expand on the limited knowledge about depression that was available in the medical record.
“The goal is to determine if chronic opioid use leads to major depressive episodes or to symptom clusters; that look like depression, such as anhedonia, vital exhaustion, apathy, and dysthymia.” Lastly, the study will seek to determine the characteristics of depression most strongly related; to whether patients with mild depression have the same risk for misuse as those with severe depression; comorbid anxiety disorders.